Jo Sung Jae, Kim Seung Ho
Department of Radiology, Inje University College of Medicine, Haeundae Paik Hospital, Haeundae-gu, Busan, Korea.
Quant Imaging Med Surg. 2019 Feb;9(2):238-246. doi: 10.21037/qims.2018.12.10.
To evaluate the association between various radiologic-pathologic findings and oncogenic Kirsten-ras (KRAS) mutation in patients with primary rectal cancer.
Seventy-five patients with primary rectal cancer who had undergone rectal magnetic resonance imaging (MRI) were included. The rectal MRI consisted of T2-weighted images in three planes, pre- and post-contrast-enhanced T1-weighted images, and axial diffusion-weighted images (b factors, 0, 1,000 s/mm). Two radiologists reviewed the MRI scans and measured the axial and longitudinal tumor lengths (LTLs), apparent diffusion coefficient (ADC), and relative contrast enhancement [signal intensity (SI) difference of tumor on pre- and post-contrast T1WI/SI of tumor on pre-contrast T1WI]. The associations among the qualitative data (tumor stage, node stage, lymphatic invasion, venous invasion, and perineural invasion), quantitative data (tumor length, ADC, relative contrast enhancement) and KRAS mutations were statistically analyzed by Fisher's exact test for the qualitative data and by the Mann-Whitney U test for the quantitative data. An area under receiver operating characteristic curve (AUC) was considered as the diagnostic performance for the prediction of KRAS mutation. Molecular-biologic results served as the reference standard.
The ratio of axial to LTL in the KRAS-mutant group (n=41) was higher than that in the wild-type group (n=34) (0.29±0.15; 0.22±0.08, P=0.0117). The AUC was 0.640 (95% CI, 0.520 to 0.747, P=0.0292) with an estimated maximum accuracy of 64%. The mean ADC of the mutant group was not significantly different from that of the wild-type group [(0.95±0.17)×10 mm/s; (0.96±0.17)×10 mm/s, P=0.6505]. The relative contrast enhancement showed no significant difference between the two groups (1.66±0.93, 1.35±0.84, P=0.1581). The other qualitative findings also did not show any significant difference (P>0.05).
The ratio of axial to LTL showed a significant difference according to KRAS mutation in patients with primary rectal cancer. However, it showed a low accuracy of 64% for prediction of KRAS mutation.
评估原发性直肠癌患者各种放射学-病理学表现与致癌性 Kirsten 大鼠肉瘤病毒癌基因(KRAS)突变之间的关联。
纳入 75 例接受直肠磁共振成像(MRI)检查的原发性直肠癌患者。直肠 MRI 包括三个平面的 T2 加权图像、对比剂增强前后的 T1 加权图像以及轴向扩散加权图像(b 值为 0、1000 s/mm²)。两名放射科医生对 MRI 扫描图像进行评估,测量肿瘤的轴向和纵向长度(LTL)、表观扩散系数(ADC)以及相对对比增强率[对比剂增强前后 T1WI 上肿瘤的信号强度(SI)差值/对比剂增强前 T1WI 上肿瘤的 SI]。采用 Fisher 精确检验对定性数据(肿瘤分期、淋巴结分期、淋巴管侵犯、静脉侵犯和神经周围侵犯)进行统计分析,采用 Mann-Whitney U 检验对定量数据(肿瘤长度、ADC、相对对比增强率)与 KRAS 突变之间的关联进行统计分析。将受试者操作特征曲线(ROC)下面积视为预测 KRAS 突变的诊断性能。分子生物学结果作为参考标准。
KRAS 突变组(n = 41)的轴向与 LTL 比值高于野生型组(n = 34)(0.29±0.15;0.22±0.08,P = 0.0117)。ROC 曲线下面积为 0.640(95%可信区间,0.520 至 0.747,P = 0.0292),估计最大准确率为 64%。突变组的平均 ADC 与野生型组无显著差异[(0.95±0.17)×10⁻³mm²/s;(0.96±0.17)×10⁻³mm²/s,P = 0.6505]。两组之间的相对对比增强率无显著差异(1.66±0.93,1.35±0.84,P = 0.1581)。其他定性表现也无显著差异(P>0.05)。
原发性直肠癌患者中,根据 KRAS 突变情况,轴向与 LTL 比值存在显著差异。然而,其预测 KRAS 突变的准确率较低,为 64%。